My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.740 +0.070 (+4.19%)

Official Closing Price Updated: 8:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >

Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 06, 2025

Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027.

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 15, 2025

Via Benzinga

A Peek at Lineage Cell Therapeutics's Future Earnings ↗

August 11, 2025

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗

March 11, 2025

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗

January 31, 2025

Via Benzinga

Lineage Cell Revenue Doubles in Q2 ↗

August 12, 2025

Via The Motley Fool

Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗

August 12, 2025

Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027.

Via Chartmill

Two Biotech Stocks Poised For Big Moves On Monday ↗

June 23, 2025

Via Benzinga

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗

January 03, 2025

Via Benzinga

Lineage Cell Therapeutics's Earnings Outlook ↗

November 13, 2024

Via Benzinga

Lineage Cell Therapeutics: Q4 Earnings Insights ↗

March 07, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 15, 2025

Via Benzinga

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

A Preview Of Lineage Cell Therapeutics's Earnings ↗

March 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 07, 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 14, 2024

Via Benzinga

Earnings Scheduled For November 14, 2024 ↗

November 14, 2024

Via Benzinga

Earnings Scheduled For March 7, 2024 ↗

March 07, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 01, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.